Stocktoria
Marker Therapeutics, Inc. MRKR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-11-08
Marker Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -363.5% | -168.7% | -440.4% | -563.3% | -3179.3% |
| Net margin | -343.0% | -162.8% | -248.8% | -851.9% | -3372.7% |
| Return on assets | -63.8% | -48.7% | -48.1% | -87.0% | -61.5% |
| Return on equity | -72.4% | -57.8% | -58.6% | -152.7% | -95.2% |
| Current ratio | 8.39 | 6.36 | 5.57 | 2.14 | 3.56 |
| Revenue growth | -46.2% | 99.1% | -5.8% | 183.0% | 148.3% |
Source: SEC EDGAR filings · CIK 0001094038 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.